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Biogenesis and function of microRNAs can be influenced by genetic variants in the pri-miRNA sequences 
leading to phenotypic variability. This study aims to identify single nucleotide polymorphisms (SNPs) 
affecting the expression levels of bone-related mature microRNAs and thus, triggering an osteoporotic 
phenotype. An association analysis of SNPs located in pri-miRNA sequences with bone mineral density 
(BMD) was performed in the OSTEOMED2 cohort (n = 2183). Functional studies were performed for 
assessing the role of BMD-associated miRNAs in bone cells. Two SNPs, rs6430498 in the miR-3679 
and rs12512664 in the miR-4274, were significantly associated with femoral neck BMD. Further, 
we measured these BMD-associated microRNAs in trabecular bone from osteoporotic hip fractures 
comparing to non-osteoporotic bone by qPCR. Both microRNAs were found overexpressed in fractured 
bone. Increased matrix mineralization was observed after miR-3679-3p inhibition in human osteoblastic 
cells. Finally, genotypes of rs6430498 and rs12512664 were correlated with expression levels of 
miR-3679 and miR-4274, respectively, in osteoblasts. In both cases, the allele that generated higher 
microRNA expression levels was associated with lower BMD values. In conclusion, two osteoblast-
expressed microRNAs, miR-3679 and miR-4274, were associated with BMD; their overexpression 
could contribute to the osteoporotic phenotype. These findings open new areas for the study of bone 
disorders.
MicroRNAs (miRNAs) have opened a new field of research for complex diseases with a genetic basis. These small 
non-coding RNAs inhibit the expression of target mRNAs by binding to their 3′-untranslated regions (3′UTRs). 
These molecules have added a new step of complexity in gene regulation, but may also help to increase our under-
standing of many multifactorial diseases that have been a mystery up to now.
1IMIM (Hospital del Mar Medical Research Institute), Universitat Autònoma de Barcelona, CIBERFES, RETICEF 
(ISCIII), Barcelona, Spain. 2Department of Genetics and Institute of Health Research INCLIVA, University of Valencia, 
Valencia, Spain. 3Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla-IDIVAL/Hospital de 
Torrelavega, Universidad de Cantabria. RETICEF, Santander, Spain. 4Unidad Metabólica Ósea, Hospital Universitario 
Insular, Universidad de Las Palmas de Gran Canaria, Canarias, Spain. 5Departamento de Medicina (USE), UGC 
Medicina Interna, Hospital Universitario Virgen Macarena, Seville, Spain. 6Servicio de Metabolismo Óseo y Mineral, 
Hospital Universitario Central de Asturias, Oviedo, Spain. 7CETIR Grup Mèdic, RETICEF, Barcelona, Spain. 8Servicio 
COT, Hospital Universitario Miguel Servet, Zaragoza, Spain. 9Servicio de Medicina Interna, Complejo Hospitalario 
Universitario de Albacete, Albacete, Spain. 10Departamento de Medicina Interna, H. Marqués de Valdecilla, 
Universidad de Cantabria, IDIVAL, RETICEF, Santander, Spain. 11Servicio de Reumatología. Hospital Universitario 
de Salamanca, RETICEF (ISCIII), IBSAL (Biomedical Research Institute of Salamanca), Salamanca, Spain. 12UGC 
Endocrinologia y Nutrición. Hospital Universitario San Cecilio. Granada, RETICEF, Ibs, Granada, Spain. 13Unidad de 
Enfermedades Metabólicas Óseas. Servicio de Medicina Interna. Fundacion Jimenez Diaz, Madrid, Spain. 14Hospital 
de la Santa Creu I Sant Pau. Institut d’Investigació Biomèdica Sant Pau, Barcelona, Spain. 15Department of Pediatrics, 
Obstetrics and Gynecology, University of Valencia, INCLIVA, Valencia, Spain. 16Hospital Universitario Río Hortega, 
Valladolid, Spain. Correspondence and requests for materials should be addressed to N.G. (email: ngarcia@imim.es)
Received: 13 July 2016
Accepted: 7 March 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 516  | DOI:10.1038/s41598-017-00641-7
miRNAs have been extensively studied in bone research, particularly their relationship to osteoporosis1–3. 
These studies clearly showed altered miRNAs profiling in serum from patients with osteoporosis, as well as in 
bone tissue after osteoporotic (OP) fracture. However, these miRNA expression signatures observed in patients 
with osteoporosis do not provide evidence of causality because the altered pattern could be a consequence of the 
disease or even unrelated to the pathogenesis.
Another approach in miRNAs studies is the association analysis between one SNP within a candidate miRNA 
(miR-SNP) or in a miRNA target site and one disease related-outcome. In this case, the associated variant is 
likely involved in the pathophysiology or confers susceptibility to develop the disease. Moreover, many evidences 
suggest that the genetics of complex traits are attributable to genetic variations that modulate gene expression, 
rather than the variations resulting in protein structure changes4. However, functional assays are needed in order 
to elucidate the role of the associated variants in the pathophysiology of the disease since the SNP could be in 
linkage disequilibrium with the true functional variant.
The aim of this study was to identify SNPs within candidate miRNAs in order to perform an association study 
between those SNPs and bone mineral density (BMD), the main outcome used to define osteoporosis. First, 
we searched for miR-SNPs in the primary miRNA transcript (pri-miRNA), which has a hairpin structure with 
a terminal loop and two single-stranded flanking regions. The pri-miRNAs are recognized and cleaved by the 
Drosha and DCGR8 complex, resulting in a shorter structure called pre-miRNA5. In this step, the sequences at 
the unpaired flanking arms and within the hairpin double-stranded stem structure are crucial to correct bind-
ing and cleavage by the Drosha-DCGR8 complex. Thus, the existence of genetic variants within the pri-miRNA 
sequences could lead to an alteration of the hairpin structure, affecting molecular processing and the underlying 
miRNA maturation6. Changes in miRNA maturation would trigger changes in miRNA abundancy, and conse-
quently a deregulation of the expression levels of target genes. Supporting this idea, large-scale in silico analyses of 
SNPs in human miRNA genes have demonstrated lower SNP densities in the miRNA sequence than their flanking 
regions or the human genome7. Hence, our study was based on the detection and subsequent genetic association 
analysis of putative functional miR-SNPs. Furthermore, associated miR-SNPs were explored in bone cells in order 
to validate the association with the OP phenotype.
Results
An overall overview of methodology and results is schematized in Fig. 1.
Association analysis with BMD. The first approach used in our study was to identify functional variants 
within microRNAs involved in bone metabolism. The minor allele frequency (MAF) of many of the miR-SNPs 
found in databases has not been assessed in European population; therefore, a validation step was necessary. In 
this regard, SNPs in microRNA sequences were firstly validated as polymorphic in patients from BARCOS subco-
hort8. Of the 53 miR-SNPs tested, 14 were validated in this cohort. However, only 5 SNPs had a MAF > 0.01 and 
were finally genotyped in the OSTEOMED2 cohort for their association analysis with LS (lumbar spine) BMD 
and FN (femoral neck) BMD (Table 1).
SNP rs6430498 in the miR-3679 was significantly associated with FN BMD in a log-additive (p value = 0.036, 
Beta coefficient [95% CI] = −0.008 [−0.015 to −0.001] and recessive model (p value = 0.021, Beta coefficient 
[95% CI] = −0.017 [−0.032 to −0.003]); and the SNP rs12512664 in the miR-4274 was also significantly asso-
ciated with FN BMD in a log-additive (p value = 0.016, Beta coefficient [95% CI] = 0.008 [0.002 to 0.015] and 
recessive model (p value = 0.01, Beta coefficient [95% CI] = 0.015 [0.004 to 0.027). For both SNPs, the genotyping 
efficiency was approximately 98%. The A alleles for rs6430498 (minority allele) and rs12512664 (majority allele) 
were found to be associated with lower BMD values.
Quantification of miRNA expression levels in total FN bone samples. The anthropometric features 
of the OP and Control groups were shown in Table 2. Using the Mann–Whitney U test, no statistical differences 
in any features were observed between both groups.
Figure 1. Schematic overview of the whole procedures, samples and results of the study.
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TARGET 
GENE miRNA SNP MAFB Association with BMD
ESR1
miR-106b rs72631827 Monomorphic
miR-130b rs72631822 Monomorphic
miR-148b rs74878365 Monomorphic
miR-18a rs41275866 Monomorphic
miR-222 rs72631825 Monomorphic
miR-373 rs80338016 Monomorphic
miR-520c rs7255628 Monomorphic
miR-93 rs72631824 Monomorphic
miR-96
rs41274239 0.0033
MAF < 0.01
rs73159662 0.0058
TGFB2
miR-141 rs34385807 Monomorphic
miR-149 rs71428439 Monomorphic
miR-182
rs77586312 Monomorphic
rs75953509 Monomorphic
rs80041074 0.0033 MAF < 0.01
miR-199b rs72631835 Monomorphic
miR-193a rs60406007 Monomorphic
miR-200b rs72563729 Monomorphic
miR-33a rs77809319 Monomorphic
miR-431 rs76090066 0.00083 MAF < 0.01
rs128840′05 Monomorphic
miR-590 rs6971711 Monomorphic
miR-7-1 rs76662330 Monomorphic
miR-7-2 rs41276930 0.005 MAF < 0.01
rs75737367 Monomorphic
PTH1R miR-339
rs13232101 Monomorphic
rs72631820 Monomorphic
rs72631831 Monomorphic
RUNX2
miR-122 rs41292412 0.0033 MAF < 0.01
miR-154 rs41286570 0.0004
IL6R
miR-124-2 rs72631829 Monomorphic
miR-124-3 rs34059726 Monomorphic
miR-125a rs12975333 Monomorphic
miR-140 rs7205289 Monomorphic
miR-320d-1 rs74826059 Monomorphic
miR-499
rs3746444 0.21 Not associated
rs7267163 0.0025 MAF < 0.01
LRP5 miR-27a rs11671784 0.0162 Not associated
IL6
miR-146a rs2910164 0.26 Not associated
miR-146b rs76149940 Monomorphic
miR-202 rs12355840 Monomorphic
miR-365-2 rs35143473 Monomorphic
VDR
miR-10a rs72631828 Monomorphic
miR-223 rs34952329 Monomorphic
CYP24A1
miR-30b rs111424617 Monomorphic
miR-30e rs112439044 Monomorphic
miR-183
rs72631833 Monomorphic
rs41281222 Monomorphic
miR-101-2 rs78851134 0.0004 MAF < 0.01
Highly 
expressed in 
HObs
miR-1282 rs11269 Monomorphic
miR-3679
rs6430498 0.35 Associated with FN BMD
rs10175383 Monomorphic
miR-4274 rs12512664 0.47 Associated with FN BMD
Table 1. Validation of miR-SNPs for the BMD association analysis. MAFB; Minor allele frequency in BARCOS 
cohort; SNPs with MAF<0.01 were excluded for genotyping. In bold; Validated SNPs for genotyping in total 
OSTEOMED2 cohort.
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MiR-3679 and miR-4274, which harbored BMD-associated SNPs in their pre-miRNA sequence (Fig. 2), were 
quantified by qPCR in order to compare the expression levels between OP and non-OP bone samples.
MiR-3679-5p was not detected in total bone samples or in cultured human osteoblast cells, but miR-3679-3p 
was present in both sample types. Therefore, only mature miR-3679-3p was assayed in the qPCR. Both miRNAs 
miR-3679-3p and miR-4274 were significantly overexpressed in the OP samples (Table 3).
Other bone miRNAs, miR-631 and miR-574-5p1, 9, were also tested in order to preclude a non-specific phe-
nomenon related to a general upregulation of gene expression. No differences were found between osteoporotic 
and non-osteoporotic bone samples (p = 0.626 and p = 0.183 respectively).
Association analysis of miRNA expression levels with genotypes of BMD-associated 
SNPs. Human primary osteoblasts (n = 38) were cultured for DNA and RNA extraction and sorted by 
Bicological groups n Age (Mean ± SD)
BMI (kg/m2) 
(Mean ± SD)
BMD (g/cm2) 
(Mean ± SD)
Osteoporotic 10 75.6 ± 6.38 27.11 ± 2.94 Fragility fracture
Non-osteoporotic 10 71.7 ± 7.36 27.42 ± 3.15 0.882 ± 0.137
Table 2. Patient characteristics for osteoporotic fracture and non-osteoporotic groups. Abbreviations: SD: 
Standard Deviation; BMI: Body Mass Index; BMD: Bone Mineral Density.
Figure 2. Predicted changes in secondary structure provoked by the BMD-associated SNPs according to 
RNAstructure web server. Black arrows tag the corresponding allele for rs6430498 in the miR-3679 and 
rs12512664 in the miR-4274.
miRNA
Biological 
Group
RQ 
(Median) IQR P value
miR-3679
Osteoporotic 89.601 220.636
0.001
Control 1.423 0.964
miR-4274
Osteoporotic 144.268 318.409
0.001
Control 1.197 2.154
Table 3. miRNA expression levels, comparison between osteoporotic and non-osteoporotic bone samples. 
Abbreviations: RQ = Relative quantification; IQR = Interquartile Range.
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genotype for both rs6430498 and rs12512664. Association between expression levels of mature miRNA miR-
3679-3p and miR-4274 with its corresponding own genotype was analyzed. A significant correlation was observed 
between miRNA levels and the genetic variant (Fig. 3). The A allele for both SNPs was associated with higher 
expression of each corresponding miRNA (miR-3674; log-additive model; p value = 0.015; recessive model; p 
value = 0.03, and miR-4274; recessive model; p value = 0.013).
Additionally, in order to corroborate that the differences among expression levels are due to genotypes “per se” 
and not for other cellular circumstances, other bone-related miRNAs1, 9 were checked in these cells. Expression 
levels of miR-320a, and miR-22-3p were measured and no differences were found irrespective of genotypes. 
Moreover, as a sensitivity test, we analyzed the miR-3679-3p and miR-4274 expression levels separated accord-
ing to the exchanged genotype amongst both miRNAs (rs12512664 and rs6430498 respectively). Once again, 
no differences were found in both miRNA analyzed (miR-3679-3p; rs12512664: p-value = 0.713 and miR-4274; 
rs6430498: p-value = 0.645).
Bioinformatic analysis. A subtle effect of the BMD-associated SNPs on secondary pre-miRNA structure 
was detected. The genetic variants rs6430498 and rs12512664 did not provoke evident changes in the loop forma-
tion on the RNAstructure web server (Fig. 2).
Among predicted targets for miR-3679-3p are WHSC1/WHSC1L1, THRAP2, SMAD2, LRP6, SOX4, WNT7A, 
and MGAT5B. The miR-3679 is encoded within MGAT5 gene. The protein encoded by this gene, the manno-
syl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, is one of the most important enzymes 
involved in the regulation of the biosynthesis of glycoprotein oligosaccharides. The most significant pathways 
regulated by this miRNA is the glycerophospholipid metabolism (p-value = 0.02) and MAPK signaling pathway 
(p-value = 0.049).
Predicted targets for miR-4274 are BTF3, LRRC1, SOCS5, RAB10, FGR, RABGEF2 and ESRRG genes. ErbB 
(p-value = 0.002), proteoglycan in cancer (p-value = 0.006) and mTOR (p-value = 0.01) signaling pathways are 
the top pathways involving gene targets for this miRNA.
In-vitro assessment of osteoblast activity and matrix mineralization. hOBs were treated with 
miR-3679-3p and miR-4274 mimics or inhibitors and their respective controls for investigating their role in 
osteoblast function (Supplemental Fig. 1).
Inhibition of miR-3679-3p significantly enhanced 10% matrix mineralization levels at 28-day culture 
(Inhibitor: 1.64 ± 0.021; control: 1.49 ± 0.056; p value = 0.004). On the other hand, overexpression of miR-
3679-3p in hOBs weakly reduces matrix mineralization although differences were not significant (Mimic: 
1.53 ± 0.085; control: 1.68 ± 0.256; p value = 0.589). No significant differences in alkaline phosphatase (ALP) 
activity and cell proliferation were observed after miR-3679-3p transfection.
For miR-4274 transfections, no changes in any parameter evaluated were found.
Discussion
Two osteoblast-related microRNAs, miR-3679 and miR-4274, were found to be associated with femoral neck 
BMD and overexpressed in OP fractured bone. These miRNAs harbor genetic variants in their pre-miRNA 
sequences that were correlated with the miRNA expression levels in human osteoblasts. Finally, inhibition of 
Figure 3. Correlation between miRNA expression levels and genotypes for miR-3679 and miR-4274. MiRNA 
expression levels are represented as a mean ± SD of the relative expression in Real-Time PCR. U6 was used 
for normalization. Samples of 38 human primary osteoblasts were used for experiments. (n) is the number of 
samples for each genotype group.
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miR-3679-3p in human osteoblastic cells increased matrix mineralization. The lower density of genetic variants in 
miRNA genes compared to other non-coding genomic regions suggests that SNPs can have a remarkable biolog-
ical role in pri-miRNAs by differential regulation of their target genes10. Hence, we chose genetic variants within 
the pri-miRNA sequences for their putative functionality. Moreover, the BMD-associated miR-SNPs in our study 
were located in the pre-miRNA molecules, which have been described to exhibit strong selective constraints11, 12.
SNPs within the pri-miRNA sequence can affect the miRNA maturation in multiple aspects, modifying 
the hairpin structure or changing the binding affinity of biogenesis enzymes to the miRNA hairpin. Moreover, 
variants can affect alternative cleavage sites of biogenesis enzymes, producing novel isomiRs or changing their 
frequency. These changes in maturation can result in altered expression of the functional miRNA, resulting in 
deregulation of target genes. Hence, several studies have suggested that functional SNPs in pri-miRNAs affect the 
processing and expression levels of mature miRNAs13.
Two mir-SNPs, rs6430498 and rs12512664, within the pre-miRNA sequence of miR-3679 and miR-4234, 
respectively, were associated with FN BMD in the OSTEOMED2 cohort. Bioinformatic analysis of the hair-
pin structure of these BMD-associated miRNAs showed no striking effect on its secondary structure caused 
by allelic changes but we cannot rule out that the expression was altered by affecting the affinity binding of the 
processing enzymes or their accessory proteins. In this regard, other studies have demonstrated that miR-SNPs 
in pre-miRNA sequences lead to altered levels of mature miRNA in vivo even though changes in its secondary 
structure are not predicted by RNAfold program14.
In our study the AA genotype for both rs6430498 and rs12512664 showed higher expression levels of miR-
3679-3p and miR-4274 in hOBs, respectively. Moreover, these miRNAs were overexpressed in OP bone samples. 
Consistently with miR-3679-3p overexpression in OP fractured bone, transfection results suggest that miR-
3679-3p negatively regulates matrix mineralization by osteoblasts which could lead to an OP phenotype. Further 
supporting these results, the A allele for both SNPs was associated with lower FN BMD levels.
In overall, predicted targets and pathways involving miR-3679-3p belong to cell cycle, differentiation and tis-
sue development, suggesting a dysfunction in bone remodeling in the osteoporotic bone. In agreement with these 
data, an impaired mineralization was observed when miR-3679-3p was overexpressed in osteoblasts. In contrast, 
analysis of targeted genes and pathways for miR-4274 suggests that this miRNA could be involved, broadly, in 
vesicular and membrane trafficking, cell migration and adhesion, and cell metabolism. That would explain why 
changes in the assayed parameters were not detected after miR-4274 transfection in osteoblasts.
Altogether, these findings suggest that these variants can play a role in bone metabolism. Since information 
about these two miRNAs is very scarce, this study could be considered as a preliminary approach presenting miR-
3679-3p and miR-4274 within the complex network of bone regulation.
Our study is strengthened by the extremely careful in control of potentially confounding characteristics 
among bone samples in terms of age, sex, BMI and metabolic diseases highly prevalent in elderly population15, 16. 
Moreover, we excluded from the study samples from patients treated with hormones and other anti-osteoporotic 
drugs that could alter the miRNA expression in bone cells17. These strict inclusion criteria support that miRNAs 
detected in our study can be more reliably considered involved in the osteoporotic phenotype.
One limitation is the use of osteoarthritic samples as control group. Due to obvious ethical reasons the col-
lection of bone from healthy individuals is not allowed. However, in an attempt to minimize this potential limi-
tation, we obtained the bone samples from a location distant from the interface between bone and cartilage and, 
therefore, as far away as possible from the osteoarthritic lesion. Moreover, although both miRNAs have found 
overexpressed in OP bone tissue, it cannot be attributed to the SNP regulation in these samples since this could 
not be analyzed due to lack of bone sample’s availability. Other limitation of the study is the need to replicate the 
association results in other cohorts because these miR-SNPs lacked linkage information with other tag-SNPs 
related to bone phenotypes. However, this is the first time that two genetic variants in human osteoblast-related 
miRNAs have been associated with FN BMD in an extensive cohort of postmenopausal women, and this associ-
ation was functionally demonstrated in bone samples.
In conclusion, two putative functional SNPs in the pre-miRNA sequence of miR-3679 and miR-4274 were 
associated with femoral neck BMD. In both cases, the allele associated with lower BMD was correlated with 
higher expression levels of mature miRNA in human osteoblastic cells. Moreover, both miRNAs were overex-
pressed in OP fractured bone. Our results open new exploratory avenues for future studies in the bone field.
Methods
Ethics Statement. The study protocols for obtaining DNA from blood samples, bone tissue samples and 
primary osteoblasts were approved by the CEIC-Parc de Salut MAR, the coordinating center (Registry number 
2010/3882/I). Methods were carried out in accordance with the approved guidelines by the CEIC-Parc de Salut 
MAR. The approved protocols were explained to potential study participants, who provided written informed 
consent before being included in the study. All studies were carried out in accordance with the principles of the 
Declaration of Helsinki as revised in 2008.
Study subjects. Genetic association analysis was performed in an observational, clinical cohort study 
(OSTEOMED2) of patients recruited from 14 medical centers in several regions of Spain. All patients were 
consecutive, unselected, postmenopausal women attended in an outpatient clinic. Patients were prospectively 
recruited regardless of BMD value (Table 4). Exclusion criteria were any history of metabolic or endocrine dis-
ease, chronic renal failure, chronic liver disease, malignancy (except superficial skin cancer), Paget’s disease of 
bone, malabsorption syndrome, and any anti-OP or bone-affecting treatment. In addition, women with early 
menopause (before the age of 40) were excluded from analysis.
BMD (g/cm2) was measured at the lumbar spine (LS) L2-L4 and at the non-dominant femoral neck (FN) using 
the dual-energy X-ray densitometers available in each participating center (Supplemental Table 1).
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Whole bone samples for qPCR miRNA quantification were obtained from the transcervical region of the 
femoral neck of postmenopausal women undergoing hip replacement due to either OP fracture (n = 10) or oste-
oarthritis in the absence of osteoporosis (n = 10) (T-score measurements [mean ± SD]: 0.616 ± 0.523) (Table 2). 
Bone was taken from a location distant from the interface between bone and cartilage and, therefore, as far away 
as possible from the osteoarthritic lesion. Again, none of the participants had a history of metabolic or endocrine 
disease, chronic renal failure, chronic liver disease, malignancy, Paget’s disease of bone, malabsorption syndrome, 
hormone replacement therapy, anti-resorptive or anabolic agents, oral corticosteroids, anti-epileptic drugs, or 
treatment with lithium, heparin, or warfarin.
SNPs selection in pri-miRNA sequences. In the first step, 9 candidate genes were selected for 
their well-known function in bone regulation: ESR1, TGFB2, PTH1R, RUNX2, IL6R, LRP5, IL6, VDR, and 
CYP24A118–23 (Table 1). Then, miRNAs that bind to the mRNA 3′UTR of these genes were identified using the 
microRNA.org website24 (http://www.microrna.org), TargetScan Human (http://www.targetscan.org) and PicTar 
(http://pictar.mdc-berlin.de). The algorithm used is based on sequence complementarity, binding energy of the 
miRNA–target duplex, evolutionary conservation of the target site sequence and target position in aligned UTRs 
of homologous genes. Some listed miRNAs target more than one bone-related gene, as for example, miR-130b, 
miR106b, miR148b and miR-93 that target both ESR1 and TGFB2 genes. These miRNAs were located in ESR1 tar-
get miRNAs in order to simplify the Table 1. Next, miRNAs with the highest expression levels in primary human 
osteoblasts (hOB) were selected (Table 1) according to results obtained in a previous miRNA array performed 
in our group (GEGSE74211; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc = GSE74211)1. Finally, SNPs 
in the pri-miRNA sequences were searched using the Ensembl (www.ensembl.org), UCSC Genome Browser 
on Human Dec. 2013 (GRCh38/hg38) Assembly25 (http://genome.ucsc.edu/), and HapMap (www.hapmap.org) 
databases.
Only those SNPs with a minor allele frequency (MAF) in Utah residents with ancestry from northern and 
western Europe (CEU) > 0.01 were included in the study; SNPs lacking published MAF were validated in par-
ticipants from the BARCOS cohort8 (included in OSTEOMED2) by means of PCR-RFLP, genotyping or Sanger 
sequencing.
Polymorphism genotyping. DNA was obtained from peripheral blood collected in EDTA tubes and geno-
typing was performed in LGC Genomics platform using KASPar v4.0 genotyping systems. To ensure genotyping 
quality, a random sample (5% of the total number of samples) was also genotyped in a separate control plate. 
There was 100% concordance between these results.
Human osteoblasts culture. Human primary osteoblasts (hOB) were obtained from trabecular bone of 
patients who underwent knee or hip replacement due to osteoarthritis. Bony tissue was cut up into small pieces, 
washed in phosphate buffered solution (PBS, Gibco by Life Technologies; Paisley, UK) to remove non-adherent 
cells, and placed on a 140 mm culture plate. Samples were incubated in hOB medium: Dulbecco’s Modified Eagle 
Medium (DMEM; Gibco; Invitrogen, Paisley, UK), supplemented with 10% fetal calf serum (FBS; Sigma-Aldrich; 
St. Louis, USA), 100 U/ml penicillin/streptomycin (Sigma-Aldrich; St. Louis, USA), 0.4% fungizone (Gibco by 
Life Technologies; Paisley, UK), and 100 ug/ml ascorbic acid (Sigma; Steinheim, Germany). Alkaline Phosphatase 
(ALP) activity and osteocalcin gene expression were measured in order to confirm the osteoblastic phenotype 
(data not shown). All experiments were performed at maximum passage 2.
Thirty eight samples were grown in parallel: one for DNA extraction and the other for RNA extraction. 
Additionally, 11 hOB samples were used for Alizarin Red, ALP and MTS assays.
Human osteoblast DNA extraction and sequencing. DNA was extracted from cultured hOBs 
using the Wizard® Genomic DNA Purification Kit (Promega) according to manufacturer's instruc-
tions. Genotypes for rs6430498 and rs12512664 were assessed by Sanger sequencing using the BigDye® 
Terminator v3.1 (Applied Biosystems) in the genomic services of Universitat Pompeu Fabra. Primers 
(Sigma-Aldrich) were designed using the Primer3 imput (v. 0.4.0) and the UCSC website: for rs6430498 in 
miR-3679, F: 5′-CGGTGAGGAGTTTTCTGAATG-3′ and R: 5′-CACCAAGCATAATAGCTAAAAATCAA-3′ 
(fragment size: 400 bp) and for rs12512664 in miR-4274, F: 5′-CATCCACTTTGGGGAGAAGT-3′ and R: 
5′-CCAAGGTACCACTGCCTCAT-3′ (fragment size: 392 bp).
RNA extraction of osteoblasts and total bone. miRNA-enriched fraction from hOB cultures 
was extracted using MiRNeasy mini kit and RNeasy MinElute Cleanup (Qiagen) according to manufacturer 
instructions.
Patient characteristic
Mean ± SD
LS BMD n = 2183 FN BMD n = 2015
Age (years) 57.61 ± 9.26 58.80 ± 8.99
Age of menopause 
(years) 48.7 ± 3.94 48.7 ± 3.92
BMI (kg/m2) 26.56 ± 4.18 26.48 ± 4.13
BMD (g/cm2) 0.870 ± 0.16 0.707 ± 0.14
Table 4. Baseline characteristics of the OSTEOMED2 cohort. Abbreviations: BMI = body mass index; 
BMD = bone mineral density; LS = lumbar spine; FN = femoral neck.
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For RNA extraction of total bone, a piece of tissue was cut out and added to QIAzol Lysis Reagent (Qiagen), 
then homogenized for 5 min using the TissueLyser system. Chloroform was added to each sample, followed by 
centrifugation for 15 min (12000 g). The upper water phase was collected and the extraction continued according 
to manufacturer’s instructions. The quality of the total RNA was verified by an Agilent 2100 Bioanalyzer pro-
file. The concentration of the purified RNA was analyzed on a spectrophotometer (Nanodrop, Thermo Fisher 
Scientific Inc).
miRNA quantification by qPCR. Using the miScript II RT kit (Qiagen), 1 µg of total RNA was 
reverse-transcribed in 20 μl reactions. cDNA from total bone was diluted x8 and cDNA from hOBs was diluted 
x16; in both cases, 2 µl were assayed in 10 µl PCR reactions in 384-well plates using MiScript Syber Green PCR 
kit according to the protocol. The sequence of the mature miRNAs selected, according to the mirBase web site, 
was used as a forward primer and the Universal primer as a reverse. U6 snRNA was used as the reference gene for 
normalization. Amplification was performed in a QuantStudio 12 K Flex Real-Time PCR (Applied Biosystems), 
and the Expression Suite software was used both for determination of relative quantification (RQ) (by 2−ΔΔCt 
method) and for melting curve analysis.
Bioinformatics analyses of BMD-associated miRNAs. Gene target prediction was assessed using 
the following six programs: PicTar (http://pictar.mdc-berlin.de), TargetScan Human (http://www.targetscan.
org), miRDB (http://mirdb.org), MiRanda (http://www.microrna.org), DIANA-TarBase (http://diana.imis.
athena-innovation.gr), and miRTarBase (http://mirtarbase.mbc.nctu.edu.tw). The DIANA-mirPath web-based 
computational tool26 was used to identify molecular pathways potentially altered by the intersection of miRNAs 
differentially expressed in fractured bone.
miRNASNP database10, RNAstructure (http://rna.urmc.rochester.edu/RNAstructureWeb) and RNAfold 
software (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) were used to predict the effect of the variants on the 
miRNA secondary structure. These predictions are based on the assumption that variants can destabilize the 
hairpin and therefore reduce the mature miRNA levels.
Cell transfection. Primary hOB cells were seeded at the following conditions: 96-well plate at 12.000 cells/
well for MTS and ALP activity assays and 24-well plate at 45.000 cells/well for Alizarin Red quantification.
Once cells reached 60–70% of confluence, transient transfections were performed using mirVana mimics and 
inhibitors of both hsa-miR-3679-3p and hsa-miR-4274. MirVana™ miRNA Mimic Negative Control #1 and mir-
Vana™ miRNA Inhibitor Negative Control #1 were used as controls. All products were purchased from Ambion® 
Life Technologies. Mimics and controls mimics were used at 100 nM and inhibitors and control inhibitors at 
400 nM. In order to monitor transfection efficiency, miRIDIAN microRNA Mimic Transfection Control with Dy547 
(Dharmacon) was transfected into the cells at the same conditions as the miRNAs tested. Transfection of miRNAs was 
carried out using Lipofectamine RNAiMAX (Invitrogen; Carlsbad, USA) according to the manufacturer’s instruction.
Alizarin Red quantification. To induce osteoblastic mineralization, hOBs (n = 4) were cultured during 
28 days with hOB medium supplemented with 5 mM β-glicerophosphate (Sigma-Aldrich, St Louis, MO, USA). 
Cells were transfected with both mimics and inhibitors of miR-3679-3p and miR-4274, and their corresponding 
controls at day 1, and day 14 after seeding. During the cell culture time period, the medium was changed once 
every 3 days.
At day 28, cells were stained with alizarin red to quantify mineralized nodules. At this time point, media was 
removed from the cell monolayer and gently washed 3 times with PBS. The cells were then fixed in 10% buffered 
formalin for 10 minutes at room temperature. Fixative was removed and cultures were washed in PBS. The cell 
layer was stained with 2% Alizarin-S (Sigma-Aldrich, St Louis, MO, USA) at ~pH 4.2 for 20 minutes. Cell prepa-
rations were washed with PBS to eliminate nonspecific staining. To quantify calcium deposition, the dye was 
leached by the addition of 10% cetylpyridinium chloride until all of dye had been drawn. Optical density was then 
quantified by spectrophotometry at 550 nm, using 10% cetylpyridinium chloride as a blank reference.
ALP activity assay. ALP activity was measured 48 hours after miRNA transfection of hOBs (n = 4) using 
the Alkaline Phosphatase Assay Kit (Colorimetric) (Abcam; Cambridge, UK) according to the manufacturer’s 
instructions.
Cell viability assay (MTS). Viable cells were determined 48 hours post-transfection of hOBs (n = 3) using 
the CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega; WI, USA), according to the manu-
facturer’s instructions.
Statistical methods. Hardy-Weinberg equilibrium (HWE) was calculated using the chi-square test. 
Multiple linear regression models were fitted to assess the association between genotyped SNPs and BMD. 
Log-additive, dominant and recessive models were tested for each SNP association analysis. Potential confound-
ers considered for adjustment were densitometer devices, body mass index (BMI) and age. Association analyses 
were performed using R software version 2.13.2 with the SNPassoc, foreign, gdata and multtest packages.
Mann-Whitney U test was performed for OP and non-OP group comparisons in the SPSS v.12.0 for Windows. 
This test was also used for treatment comparisons between miRNA mimics or inhibitors and their respective 
controls.
Linear regression was used to analyze the association between miRNA expression levels and sample geno-
types. Log-additive, dominant and recessive models were tested for each miRNA analysis. Correlation analyses 
were performed using R software version 2.13.2 with the SNPassoc and foreign packages.
All analyses were two-tailed, and p-values < 0.05 were considered significant.
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